Document Detail


Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.
MedLine Citation:
PMID:  11555565     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A randomized, placebo-controlled, multicenter trial evaluated the safety and efficacy of 300 mg aerosolized tobramycin solution for inhalation (TSI) administered twice daily for 4 weeks in 74 bronchiectasis patients colonized with Pseudomonas aeruginosa (PA). Patients were evenly divided between TSI therapy and placebo. After 2 weeks of treatment, patients treated with TSI had a mean reduction in sputum PA density of 4.8 log(10.) This reduction was maintained for the duration of treatment. The placebo group showed no change in PA density during the study. Two weeks after the end of therapy, PA had been eradicated in 13 TSI-treated patients. PA was not eradicated in any placebo patients. Among those colonized with Staphylococcus aureus at baseline, 6 of 9 patients in the TSI group and 2 of 9 patients in the placebo group were culture negative for this organism 2 weeks posttreatment. Sixty-two percent of TSI-treated patients were judged by a physician as having an improved general health status, compared with 38% of placebo-treated patients. Dyspnea, wheezing, and chest tightness were reported more frequently in the TSI-treated patient group than in the placebo-treated patient group.
Authors:
L A Couch
Related Documents :
9185235 - The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin.
16129715 - Body composition and hormonal adaptations associated with forskolin consumption in over...
15533195 - The placebo response complex.
17035165 - The effects of caffeine ingestion on performance time, speed and power during a laborat...
23104185 - Effects of a cognitive-behavioral self-help program on depressed mood for people with p...
611495 - Efficacy of lincomycin feed medication for the control of necrotic enteritis in broiler...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Chest     Volume:  120     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-09-13     Completed Date:  2001-10-04     Revised Date:  2009-04-09    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  114S-117S     Citation Subset:  AIM; IM    
Affiliation:
Department of Pulmonary and Critical Care Medicine, The University of Texas Health Center at Tyler, Tyler, TX 75708-3154, USA. Leslie.couch@uthct.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aerosols
Bronchiectasis / drug therapy*,  microbiology
Colony Count, Microbial
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Forced Expiratory Volume / drug effects
Humans
Male
Microbial Sensitivity Tests
Nebulizers and Vaporizers*
Pseudomonas Infections / drug therapy*,  microbiology
Sputum / microbiology
Staphylococcal Infections / drug therapy,  microbiology
Tobramycin / administration & dosage*,  adverse effects
Treatment Outcome
Vital Capacity / drug effects
Chemical
Reg. No./Substance:
0/Aerosols; 32986-56-4/Tobramycin
Comments/Corrections
Comment In:
Chest. 2009 Mar;135(3):886   [PMID:  19265108 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Administration of aerosolized antibiotics in cystic fibrosis patients.
Next Document:  Microbiological and immunologic considerations with aerosolized drug delivery.